{"analyses":[{"ciLowerLimit":"-0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.65","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.323","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9526","paramType":"LS Mean Difference (Net)","paramValue":"0.02","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.313","value":"3.17"},{"groupId":"OG001","spread":"0.315","value":"3.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"754"},{"groupId":"OG001","value":"758"}],"units":"Participants"}],"description":"Duration of stay in the ICU in days.","dispersionType":"Standard Error","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All participants randomly assigned to study intervention with non-missing baseline NIAID OS and at least 1 postbaseline NIAID OS observation.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28","title":"Duration of Stay in the Intensive Care Unit (ICU) in Days","type":"SECONDARY","unitOfMeasure":"days"}